Objective: Effective treatment for primary Sjögren’s syndrome (pSS) is not available. pSS
immunopathology involves a variety of immune-cells and dysregulated pathways; targeting …

Objectives To analyse the influence of geolocation and ethnicity on the clinical presentation
of primary Sjögren's syndrome (SjS) at diagnosis. Methods The Big Data Sjögren Project …

Background Primary Sjögren's syndrome is a systemic autoimmune disease characterised
by secretory gland dysfunction, for which no effective therapy is available. Based on the …

Objective To characterize the systemic phenotype of primary Sjögren’s syndrome at
diagnosis by analysing the EULAR-SS disease activity index (ESSDAI) scores. Methods The …

Background. Atypical HUS (aHUS) is thought to be caused by predisposing mutations in
genes encoding complement (regulating) proteins, such as Factor H (CFH), Factor I (IF), …

Primary Sjögren's syndrome (pSS) is a systemic auto-immune disease typified by dryness of
the mouth and eyes. A majority of patients with pSS have a type-I interferon (IFN)-signature, …

Objectives To assess to what extent leflunomide (LEF) and hydroxychloroquine (HCQ)
therapy in patients with primary Sjögren’s syndrome (RepurpSS-I) targets type I IFN-associated …

With much interest, we read the comments 1 of our colleagues Yavuz and Rönnblom regarding
our manuscript on galectin-9 as an easy to measure biomarker to detect the interferon (…

Chapter 3 Additive immunosuppressive effect of leflunomide and hydroxychloroquine supports
rationale for combination therapy for Sjögren’s syndrome Chapter 4 Clinical efficacy of …

Background. A recent clinical trial showed clinical efficacy for combination therapy with
leflunomide (LEF) and hydroxychloroquine (HCQ) in patients with primary Sjögren’s syndrome (…